A Double-blind, Placebo-controlled Study Evaluating the Pharmacodynamic Effects of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) on Hypothalamic-pituitary-adrenal Axis Function in Outpatients With Major Depressive Disorder
Latest Information Update: 29 May 2012
At a glance
- Drugs SSR 149415 (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Sanofi
- 29 May 2012 New trial record